Mutations in Exons 18 to 21
Conditions
Brief summary
While current mutational analyses comprise exons 19 and 21 in which the majority of EGFR-mutations occur, this study aims at investigating the relevance of exon 18 and 20 mutations. Therefore, the investigators analyse 500 routine tumor samples with respect to the above mentioned exons and correlate the results to the clinical outcome. This approach will enable us to potentially identify patients that might in the future benefit from targeted therapy (EGFR-inhibition).
Interventions
None listed
Sponsors
AstraZeneca
Charite University, Berlin, Germany
Provitro GmbH
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* NSCLC Stadium III-IV
Exclusion criteria
* no NSCLC or different stadium
Countries
Germany
Outcome results
None listed